Please find attached newspaper copies regarding notice intimating the investors about the opening of a special window for transfer and dematerialisation of physical shares.
Panacea Biotec is pleased to inform the launch of the DENSTAR project which will work to advance the licensure of the dengue vaccine DengiAll in sub-Saharan Africa (sSA) and to facilitate its broader global use. A copy of the Press Release is attached herewith.
Please find attached details of shares dematerialised during May 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
Please find attached copies of newspaper publication of Audited Financial Results for the quarter and financial year ended March 31, 2026.
Please find attached results
We would like to inform you that the Board of Directors has at its meeting held today i.e. 30.05.2026 approved the appointment of Mr. Rajinder Singh Manku as an additional director in the capacity of non-executive independent director, for a term of 5 years w.e.f. July 01, 2026.
We would like to inform you that the Board of Directors has at its meeting held today, i.e. Saturday, May 30, 2026, inter-alia, considered and approved: 1. the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026. The same was also reviewed by the Audit Committee in its meeting held on May 29, 2026. A copy of the said statements of financial results along with the Auditors’ Report. 2. Passing over of dividend on the equity as well as preference shares of the Company for the financial year 2025-26, on account of losses during the year. 3. The appointment of Mr. Rajinder Singh Manku (DIN: 09706881) as an additional director in the capacity of non-executive independent director, not liable to retire by rotation, for a term of 5 consecutive years w.e.f. July 01, 2026.
We would like to inform you that the Board of Directors of the Company's material wholly owned subsidiary, Panacea Biotec Pharma Ltd., has in its meeting held today i.e. 29.05.2026 , inter-alia, approved the appointment / re-appointment of directors. Intimation with requisite details is enclosed herewith.
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 129.19 | 143.02 | 150.50 | 136.46 | 115.72 | 147.35 | 163.49 | 132.53 | 166.70 | 141.13 | 165.19 | 166.75 |
| YOY Revenue Growth % | 16.7% | 36.05% | 30.64% | 5.84% | -10.43% | 3.03% | 8.63% | -2.88% | 44.05% | -4.22% | 1.04% | 25.82% |
| Other Income | 6.08 | 3.23 | 5.68 | 10.81 | 3.80 | 4.65 | 3.62 | 8.59 | 5.67 | 6.40 | 2.28 | 2.55 |
| Total Income | 135.27 | 146.25 | 156.18 | 147.27 | 119.52 | 152.00 | 167.11 | 141.12 | 172.37 | 147.53 | 167.47 | 169.30 |
| Total Expenses + | 149.98 | 156.80 | 160.61 | 152.13 | 139.31 | 150.01 | 165.50 | 168.87 | 177.13 | 169.40 | 163.75 | 173.26 |
| Cost of Materials Consumed | 57.32 | 59.78 | 47.83 | 45.53 | 40.24 | 41.77 | 48.74 | 83.32 | 72.71 | 46.58 | 90.17 | 80.78 |
| Employee Benefit Expense | 35.97 | 37.52 | 37.65 | 38.43 | 37.50 | 43.44 | 42.98 | 49.13 | 45.72 | 47.71 | 40.53 | 46.82 |
| Other Expenses | 48.67 | 50.87 | 45.68 | 54.32 | 50.49 | 53.72 | 50.00 | 58.20 | 44.94 | 52.27 | 44.99 | 40.97 |
| Operating Profit | -20.79 | -13.78 | -10.11 | -15.67 | -23.59 | -2.66 | -2.01 | -36.34 | -10.43 | -28.27 | 1.44 | -6.51 |
| OPM % | -16.1% | -9.6% | -6.7% | -11.5% | -20.4% | -1.8% | -1.2% | -27.4% | -6.3% | -20% | 0.9% | -3.9% |
| Profit Before Tax + | 13.03 | -7.78 | -1.65 | -2.12 | -17.05 | 4.76 | 4.38 | -0.04 | 6.56 | -19.17 | 6.49 | -1.25 |
| Tax Expense | 2.05 | 0.51 | 0.55 | -0.13 | -1.17 | 0.05 | -0.06 | 1.95 | 2.60 | -5.16 | 2.60 | -0.25 |
| Tax % | 15.7% | - | - | - | - | 1.1% | -1.4% | - | 39.6% | - | 40.1% | - |
| Profit After Tax | 10.98 | -8.29 | -2.20 | -1.99 | -15.88 | 4.71 | 4.44 | -1.99 | 3.96 | -14.01 | 3.89 | -1.00 |
| EPS (Basic) | 1.79 | -1.35 | -0.37 | -0.23 | -2.59 | 0.77 | 0.74 | -0.31 | 0.66 | -2.27 | 0.65 | 0.08 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 639.77 | 559.09 | 559.17 | 459.95 | 661.23 | 624.81 | 544.06 |
| YOY Revenue Growth % | 14.43% | -0.01% | 21.57% | -30.44% | 5.83% | 14.84% | - |
| Other Income | 16.90 | 20.66 | 25.80 | 51.66 | 10.97 | 9.98 | 29.69 |
| Total Income | 656.67 | 579.75 | 584.97 | 511.61 | 672.20 | 634.79 | 573.75 |
| Total Expenses + | 683.54 | 623.69 | 619.52 | 601.47 | 899.59 | 779.11 | 535.21 |
| Cost of Materials Consumed | 290.24 | 214.07 | 210.46 | 211.03 | 281.25 | 168.48 | 179.30 |
| Employee Benefit Expense | 180.78 | 173.05 | 149.57 | 126.48 | 182.94 | 156.17 | 142.32 |
| Other Expenses | 183.17 | 212.41 | 199.54 | 178.77 | 229.95 | 187.37 | 213.59 |
| Operating Profit | -43.77 | -64.60 | -60.35 | -141.52 | -238.36 | -154.30 | 8.85 |
| OPM % | -6.8% | -11.6% | -10.8% | -30.8% | -36% | -24.7% | 1.6% |
| Profit Before Exceptional | -26.87 | -43.94 | -34.55 | -89.86 | -227.39 | -144.32 | -156.15 |
| Exceptional Items | 19.50 | 35.99 | 36.03 | 102.66 | 1,676.21 | 0.00 | -15.40 |
| Profit Before Tax + | -7.37 | -7.95 | 1.48 | 12.80 | 1,448.82 | -144.32 | -171.55 |
| Tax Expense | -0.21 | 0.77 | 2.98 | 46.55 | 370.91 | 3.33 | 22.74 |
| Tax % | - | - | 201.4% | 363.7% | 25.6% | - | - |
| Profit After Tax | -7.16 | -8.72 | -1.50 | -33.75 | 1,077.91 | -147.65 | -194.29 |
| EPS (Basic) | -0.88 | -1.37 | -0.19 | -5.51 | 175.98 | -24.11 | -31.72 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Non-Current Assets + | 749.13 | 744.57 | 755.51 | 702.85 | 741.95 | 667.85 | 0.00 |
| Property, Plant & Equipment | 553.27 | 543.39 | 560.04 | 588.33 | 587.81 | 606.65 | 0.00 |
| Capital Work in Progress | 99.97 | 93.51 | 74.72 | 28.01 | 4.91 | 21.24 | 0.00 |
| Non-Current Investments | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.00 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Intangible Assets | 6.77 | 7.72 | 9.22 | 11.62 | 1.47 | 2.05 | 0.00 |
| Current Assets + | 513.04 | 545.18 | 485.17 | 562.31 | 1,000.55 | 474.22 | 0.00 |
| Inventories | 192.79 | 213.67 | 177.94 | 202.09 | 212.72 | 174.14 | 0.00 |
| Trade Receivables | 73.52 | 72.56 | 57.42 | 60.09 | 131.66 | 84.68 | 0.00 |
| Cash and Cash Equivalents | 57.31 | 82.13 | 47.17 | 39.85 | 50.35 | 52.08 | 0.00 |
| Current Investments | 10.03 | 3.15 | 40.36 | 13.42 | 5.00 | 0.00 | 0.00 |
| LIABILITIES & EQUITY | |||||||
| Total Equity | 828.88 | 830.62 | 838.23 | 840.11 | 845.82 | -231.69 | 0.00 |
| Equity Share Capital | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 | 0.00 |
| Other Equity | 828.71 | 828.66 | 835.92 | 837.48 | 842.67 | -234.82 | 0.00 |
| Non-Current Liabilities | 84.61 | 92.14 | 93.62 | 99.22 | 133.92 | 984.85 | 0.00 |
| Current Liabilities | 348.68 | 366.99 | 308.83 | 329.73 | 800.16 | 425.66 | 0.00 |
| Total Liabilities | 433.29 | 459.13 | 402.45 | 431.05 | 936.68 | 1,410.51 | 0.00 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activities | 16.68 | -27.37 | -0.10 | -423.46 | -108.43 | 106.76 | 0.00 |
| Cash from Investing Activities | -40.49 | 64.98 | 10.23 | 430.33 | 1,282.57 | -47.68 | 0.00 |
| Cash from Financing Activities | -1.05 | -2.66 | -2.81 | -18.38 | -1,175.85 | -47.11 | 0.00 |
| Net Increase/Decrease in Cash | -24.82 | 34.96 | 7.32 | -10.50 | -1.73 | 11.86 | 0.00 |